| pathology | Demonstrated benefit and harm | k | | | |
|---|
| advanced breast cancer (metastatic) | versus endocrine therapy alone No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Hyams | cediranib + fulvestrant vs fulvestrant | | | |
| Trial | Treatments | Patients | Method |
|---|
| Hyams | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
| lung cancer (metastatic) | versus No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Laurie, 2014 | cediranib 20mg daily to carboplatin/paclitaxel (n=-9) vs. (n=-9) | patients with advanced non-small cell lung cancer | double-blind Sample size: -9/-9 Primary endpoint: FU duration: | | Dy, 2013 | (n=-9) vs. (n=-9) | first-line therapy in advanced non-small-cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: phase II | | Goss, 2010 | (n=-9) vs. (n=-9) | initial therapy for advanced non-small-cell lung cancer | double-blind Sample size: -9/-9 Primary endpoint: FU duration: phase II/III |
|
| lung cancer (metastatic) | versus chemotherapy No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ASCEND-4, 2017 | ceritinib vs chemotherapy | PFS 0.55 [0.42; 0.73] median 16.6 vs. 8.1 | | OS 0.73 [0.50; 1.07] median NR vs. 26.2 | | ASCEND 5, 2017 | ceritinib vs pemetrexed or docetaxel | | | |
| Trial | Treatments | Patients | Method |
|---|
| ASCEND-4, 2017 | oral ceritinib 750 mg/day (n=189) vs. platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 weeks for four cycles followed by maintenance pemetrexed (n=187) | untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC | open-label Sample size: 189/187 Primary endpoint: pfs FU duration: | | ASCEND 5, 2017 | Oral LDK378 750 mg once daily (n=-9) vs. pemetrexed or docetaxel (n=-9) | patients previously treated with chemotherapy (platinum doublet) and crizotinib | Sample size: -9/-9 Primary endpoint: PFS FU duration: |
|
